
    
      Clinical Phase: I/II

      Population: Patients with Amyotrophic Lateral Sclerosis.

      Project Design: One arm, non-blinded, open label study

      Planned Sample Size: 20 patients

      Investigational Medicinal Product: active IMP - mesenchymal stem cells isolated from
      Wharton's jelly

      Screening:

      Three visits on site to check the eligibility criteria (around 90, 60 and 30 days before
      first IMP administration)

      Treatment (IMP administration):

      Each patient will receive IMP three times: on baseline (day 0), 30 and 60 days after baseline
      (+/- 7 days).

      Administration route: intrathecal

      Follow up:

      Duration: 18 months after first IMP administration Four on-site visits (3, 6, 9, 12 months
      after first IMP administration) and seven phone visits (4, 5, 7, 8, 10, 11 and 18 months
      after first IMP administration)
    
  